Incidence and risk of vaginal candidiasis associated with sodium-glucose cotransporter 2 inhibitors in real-world practice for women with type 2 diabetes-Reference-Cited by-同舟云学术

Incidence and risk of vaginal candidiasis associated with sodium-glucose cotransporter 2 inhibitors in real-world practice for women with type 2 diabetes

Published:2018-10-19 Issue:2 Volume:10 Page:439-445
ISSN:2040-1116
Container-title:Journal of Diabetes Investigation
language:en
Short-container-title:J Diabetes Investig

Author:

Yokoyama Hiroki¹^ORCID,Nagao Ami¹,Watanabe Sanae¹,Honjo Jun¹

Affiliation:

1. Internal Medicine; Jiyugaoka Medical Clinic; Obihiro Japan

Publisher

Wiley

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdi.12912/fullpdf

Reference18 articles.

1. Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study;Brownrigg;Lancet Diabetes Endocrinol,2016

2. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences;Gallo;Diab Vasc Dis Res,2015

3. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes;Zinman;N Engl J Med,2015

4. Empagliflozin and progression of kidney disease in Type 2 diabetes;Wanner;N Engl J Med,2016

5. Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes;Leon;BMC Infect Dis,2002

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment and correction of local antimicrobial protection factors in women with chronic recurrent vulvovaginal candidiasis and type 2 diabetes mellitus;Gynecology;2024-06-10

2. Fungal ball in the bladder;Visual Journal of Emergency Medicine;2024-04

3. POSSIBILITIES OF GYNECOLOGICAL DRUG TREATMENTS IN VAGINAL AND VULVAR CANDIDIASIS CAUSED BY DIABETES ASSOCIATED WITH ORAL PATHOLOGY;ROM J ORAL REHABIL;2024

4. Insights and advances in recurrent vulvovaginal candidiasis;PLOS Pathogens;2023-11-10

5. Risk of urogenital infections in non-diabetic patients treated with sodium glucose transporter 2 (SGLT2) inhibitors. Systematic review and meta-analysis;Archivio Italiano di Urologia e Andrologia;2023-06-13